Gero
- 20/10/2023
- Series A
- $6,000,000
We are a preclinical stage AI drug discovery company with a mission to eliminate age-related diseases
We use AI to build clinically relevant disease phenotypes in real-world human data and identify diseases with shared biology. Then WES-enabled genetic study on these phenotypes allows us to discover novel targets applicable to several indications at once.
You can find our publications here: https://gero.ai/publications
- Industry Biotechnology
- Website https://gero.ai/
- LinkedIn https://www.linkedin.com/company/gero/about/
Related People
Peter FedichevCo Founder
I'm an entrepreneur and scientist with over 20 years of experience in academic research and biotech business, co-founded three biotech companies: Quantum Pharmaceuticals, a drug discovery company, and Gero, a longevity startup and GlyNeura, a biotech-pharma company aiming to cure Neurodegenerative Diseases. My scientific background lies in the field of condensed matter physics, biophysics and bioinformatics. I've conducted research at Kurchatov Institute, one of the leading science government agencies in Russia, AMOLF, an academic institute for fundamental physics in the Netherlands, and the University of Innsbruck. I earned my M.S. in theoretical physics from the Moscow Institute of Physics and Technology and Ph.D. from the University of Amsterdam and currently have over 65 publications (h=28) in peer-reviewed journals. I believe that nothing beats the joy of discovery, the power of physics to uncover the laws of nature, and the challenge of aging research. My dream is to beat aging and experience life in space.